Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Junegoo Lee"'
Publikováno v:
PLoS ONE, Vol 7, Iss 1, p e30246 (2012)
Mechanisms of resistance for HNSCC to cisplatin (CDDP), the foundational chemotherapeutic agent in the treatment of this disease, remain poorly understood. We previously demonstrated that cisplatin resistance (CR) can be overcome by targeting Trk rec
Externí odkaz:
https://doaj.org/article/6d7c80affef74ea8bf212024e1c18196
Autor:
Mariah J. Berner, Lily Baek, Junegoo Lee, Philip L. Lorenzi, Mei Leng, Alexander B. Saltzman, Anna Malovannaya, Lacey E. Dobrolecki, Christina Sallas, Michael T. Lewis, Gloria V. Echeverria
Publikováno v:
Cancer Research. 83:P6-11
BACKGROUND: Nearly 50% of patients with triple negative breast cancer (TNBC) treated with neoadjuvant chemotherapy (NACT) retain residual tumors resulting in high rates of metastatic relapse and poor overall survival. Residual tumors surviving NACT (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c47b669b4dc7c0b0dc2d0b018d0049a5
https://doi.org/10.1158/1538-7445.sabcs22-p6-11-10
https://doi.org/10.1158/1538-7445.sabcs22-p6-11-10
Autor:
Katherine E. Pendleton, Mokryun L. Baek, Junegoo Lee, Lin Tan, Hannah L. Johnson, Lacey E. Dobrolecki, James P. Barrish, Michael T. Lewis, Philip L. Lorenzi, Fabio Stossi, Gloria V. Echeverria
Publikováno v:
Cancer Research. 83:P6-11
Background: Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype for which limited targeted therapies are available. Therefore, conventional chemotherapy remains the backbone of standard neoadjuvant treatment (NACT) for TNBC pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::57f1fa69cc4206aa91aa6feea094f5ab
https://doi.org/10.1158/1538-7445.sabcs22-p6-11-15
https://doi.org/10.1158/1538-7445.sabcs22-p6-11-15
Autor:
Lily Baek, Junegoo Lee, Katherine E. Pendleton, Mariah J. Berner, Emily Goff, Lin Tan, Sara Martinez, Iqbal Mahmud, Argenis Arriojas, Alexander Zhurkevich, Tao Wang, Matthew Meyer, Bora Lim, James P. Barrish, Weston Porter, Kourosh Zarringhalam, Philip L. Lorenzi, Gloria V. Echeverria
Publikováno v:
Cancer Research. 83:P6-11
Background: Neoadjuvant chemotherapy (NACT) used for triple-negative breast cancer (TNBC) eradicates tumors in only 45% of patients. TNBC patients with substantial residual cancer burden have poor metastasis-free and overall survival rates. Our previ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8bfd14c1372d6b3a08806899d51735c9
https://doi.org/10.1158/1538-7445.sabcs22-p6-11-14
https://doi.org/10.1158/1538-7445.sabcs22-p6-11-14
Autor:
Mokryun L. Baek, Junegoo Lee, Katherine E. Pendleton, Mariah J. Berner, Emily B. Goff, Lin Tan, Sara A. Martinez, Iqbal Mahmud, Tao Wang, Matthew D. Meyer, Bora Lim, James P. Barrish, Weston Porter, Philip L. Lorenzi, Gloria V. Echeverria
Publikováno v:
Oncogene
Neoadjuvant chemotherapy (NACT) used for triple negative breast cancer (TNBC) eradicates tumors in approximately 45% of patients. Unfortunately, TNBC patients with substantial residual cancer burden have poor metastasis free and overall survival rate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bafa58e4c0d1f2889d32411063d87891
https://europepmc.org/articles/PMC10069007/
https://europepmc.org/articles/PMC10069007/
Autor:
Mokryun L. Baek, Junegoo Lee, Katherine E. Pendleton, Mariah J. Berner, Emily B. Goff, Lin Tan, Sara A. Martinez, Tao Wang, Matthew D. Meyer, Bora Lim, James P. Barrish, Weston Porter, Philip L. Lorenzi, Gloria V. Echeverria
Neoadjuvant chemotherapy (NACT) used for triple negative breast cancer (TNBC) eradicates tumors in approximately 45% of patients. Unfortunately, TNBC patients with substantial residual cancer burden have poor metastasis free and overall survival rate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::717625ad35b5c6c96520bf5e771ec8c7
https://doi.org/10.1101/2022.02.25.481996
https://doi.org/10.1101/2022.02.25.481996
Autor:
Lily Baek, Junegoo Lee, Mariah J. Berner, Katherine E. Pendleton, Emily B. Goff, Karen Wang, James P. Barrish, Bora Lim, Philip J. Lorenzi, Weston Porter, Michael T. Lewis, Gloria V. Echeverria
Publikováno v:
Cancer Research. 82:6384-6384
Mitochondrial metabolism plays a key role in triple negative breast cancer (TNBC) aggressiveness. As TNBC has limited targeted therapy options, chemotherapies remain the mainstay treatment. Nearly 50% of TNBC patients harbor substantial residual canc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b761867877aa06cd4ea7bd0f27119327
https://doi.org/10.1158/1538-7445.am2022-6384
https://doi.org/10.1158/1538-7445.am2022-6384
Autor:
Lily Baek, Mariah Berner, Junegoo Lee, Katherine Pendleton, Karen Wang, Emily B. Goff, James P. Barrish, Bora Lim, Michael T. Lewis, Philip L. Lorenzi, Weston Porter, Gloria V. Echeverria
Publikováno v:
Cancer Research. 82:PR009-PR009
Triple negative breast cancer (TNBC) is an aggressive disease with extremely limited targeted therapeutic options. Thus, standard cytotoxic chemotherapies (typically sequential and/or combined anthracyclines, taxanes, and/or platinums) remain a mains
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5935f9527eed8ea15f1dde35c5f088df
https://doi.org/10.1158/1538-7445.evodyn22-pr009
https://doi.org/10.1158/1538-7445.evodyn22-pr009
Autor:
Lily Mokryun Baek, Junegoo Lee, James P. Barrish, Bora Lim, Jeffrey T. Chang, Phillip L. Lorenzi, Weston Porter, Gloria V. Echeverria
Publikováno v:
Cancer Research. 82:P4-01
BACKGROUND: Neoadjuvant chemotherapy (NACT) used for triple negative breast cancer (TNBC) eradicates tumors in only 45% of patients. TNBC patients with substantial residual cancer burden have poor metastasis free and overall survival rates. Therefore
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f3663d8cf634c2aef8c9a862ee52c1c2
https://doi.org/10.1158/1538-7445.sabcs21-p4-01-08
https://doi.org/10.1158/1538-7445.sabcs21-p4-01-08
Autor:
Jeffrey N. Myers, Yoko Takahashi, Tilahun Jiffar, Michael E. Kupferman, Ehab Y. Hanna, Junegoo Lee, Curtis R. Pickering, Diana Bell
Publikováno v:
Head & Neck. 38:E1926-E1934
Background Sinonasal undifferentiated carcinoma (SNUC) is a rare and aggressive cancer. Despite multimodal therapy, the prognosis in SNUC remains poor, and new therapies are needed. Thus, the purpose of this study was to explore potential therapeutic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f238399276536e7e2370503044d4abdc
https://doi.org/10.1002/hed.24350
https://doi.org/10.1002/hed.24350